RXRX
$3.47-16.71%
Recursion Pharmaceuticals Inc.Stock · HealthcareRussell 2000 0.06%Nasdaq Composite 0.006%US Stock Market 0.003%Russell 3000 0.002%
RXRX financial statements
The full income statement, balance sheet, and cash-flow statement for Recursion Pharmaceuticals Inc. (RXRX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 281.0M2024-09 286.1M2024-12 396.8M2025-03 406.4M2025-06 432.8M2025-09 491.8M2025-12 528.2M2026-03 530.6M2026-06 535.3M+90.5% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 74.7M+26.9% | 58.8M+32.0% | 44.6M+11.9% | 39.8M+291.5% | 10.2M+156.9% | |
| Cost of revenue | 71.0M+56.8% | 45.2M+6.2% | 42.6M-11.8% | 48.3M | 0.00 | |
| — | — | — | — | 193M+117.8% | ||
| Research & development | 475M+51.2% | 314M+30.3% | 241M+54.9% | 156M+15.1% | 135M+113.6% | |
| Selling, general & administrative | 177M-0.9% | 178M+60.8% | 111M+35.8% | 81.6M+41.5% | 57.7M+128.4% | |
| General & administrative | 177M-0.9% | 178M+60.8% | 111M+35.8% | 81.6M+41.5% | 57.7M+128.4% | |
| Restructuring | 9.84M | — | — | — | — | |
| Amortization of intangibles | 50.3M+167.6% | 18.8M+121.2% | 8.50M+2142.7% | 379K+24.7% | 304K+141.3% | |
| Operating income | -648M-35.3% | -479M-36.8% | -350M-42.5% | -246M-34.4% | -183M-116.0% | |
| Interest expense | 1.81M+15.1% | 1.57M+1520.6% | 97.0K+76.4% | 55.0K-98.1% | 2.95M+117.1% | |
| Other non-operating income | 3.24M-77.2% | 14.2M-20.7% | 17.9M+186.9% | 6.25M+268.8% | -3.70M-54.9% | |
| Pre-tax income | -645M-38.8% | -465M-39.9% | -332M-38.7% | -239M-28.4% | -186M | |
| Income tax | -136K+87.9% | -1.13M+72.3% | -4.06M | 0.00 | 0.00 | |
| Net income | -645M-39.1% | -464M-41.3% | -328M-37.0% | -239M-28.4% | -186M-114.3% | |
| -$1.44+14.8% | -$1.69-7.0% | -$1.58-16.2% | -$1.36+8.7% | -$1.49+62.7% | ||
| EPS (basic) | -$1.44+14.8% | -$1.69-7.0% | -$1.58-16.2% | -$1.36+8.7% | -$1.49+62.7% | |
| Weighted-avg shares (basic) | 447M+63.2% | 274M+31.9% | 208M+18.4% | 176M+40.0% | 125M+475.5% | |
| Weighted-avg shares (diluted) | 447M+63.2% | 274M+31.9% | 208M+18.4% | 176M+40.0% | 125M+475.5% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 813M+13.8% | 714M+63.0% | 438M-23.1% | 570M+6.6% | 535M+100.7% | ||
| Cash & equivalents | 743M+25.1% | 594M+51.8% | 392M-28.8% | 550M+92.9% | 285M+8.8% | |
| Short-term investments | — | — | — | 0.00-100.0% | 231M | |
| Accounts receivable | — | — | — | 0.00-100.0% | 34.0K-78.2% | |
| Prepaid expenses | 11.7M-60.3% | 29.6M | — | — | — | |
| Other current assets | 28.6M-25.0% | 38.1M-5.3% | 40.2M+153.6% | 15.9M+111.2% | 7.51M+248.7% | |
| 1.47B+1.8% | 1.45B+121.6% | 654M-6.8% | 701M+14.9% | 610M+104.4% | ||
| Property, plant & equipment | 104M-26.3% | 141M+63.1% | 86.5M-1.9% | 88.2M+36.3% | 64.7M+149.3% | |
| Operating lease right-of-use | 45.3M-31.2% | 65.9M+95.7% | 33.7M+1.2% | 33.3M+1.1% | 32.9M | |
| Goodwill | 162M+8.9% | 149M+186.0% | 52.1M+6398.9% | 801K+0.0% | 801K+0.0% | |
| Intangible assets | 310M-7.7% | 336M+821.6% | 36.4M+2690.4% | 1.31M-5.7% | 1.39M-18.0% | |
| Deferred tax assets | 957K-50.5% | 1.93M | 0.00 | — | — | |
| Other non-current assets | 12.8M+44.5% | 8.82M+3281.2% | 261K | 0.00-100.0% | 35.0K-94.6% | |
| 148M-21.2% | 187M+101.2% | 93.2M-7.1% | 100M+114.9% | 46.7M+102.0% | ||
| Accounts payable | 18.1M-16.2% | 21.6M+446.7% | 3.95M-13.8% | 4.59M+62.7% | 2.82M+162.5% | |
| Accrued liabilities | 70.2M-14.2% | 81.9M+75.6% | 46.6M+41.7% | 32.9M+1.8% | 32.3M+208.4% | |
| Deferred revenue | 37.6M-39.1% | 61.8M+69.6% | 36.4M-35.8% | 56.7M+467.3% | 10.0M+0.0% | |
| Short-term & current debt | 9.09M+7.9% | 8.43M+20448.8% | 41.0K | — | — | |
| Current lease liability | 12.7M-8.2% | 13.8M+125.6% | 6.12M+2.8% | 5.95M | 0.00 | |
| Finance lease liability (current) | 8.97M+7.9% | 8.31M | 0.00 | — | — | |
| 343M-17.0% | 414M+117.5% | 190M-11.7% | 215M+219.7% | 67.4M+19.2% | ||
| Long-term debt | 9.56M-49.7% | 19.0M+1627.7% | 1.10M | — | 723K | |
| Deferred revenue (non-current) | 114M-4.0% | 119M+131.8% | 51.2M-27.1% | 70.3M+953.9% | 6.67M-60.0% | |
| Non-current lease liability | 46.6M-30.6% | 67.3M+54.9% | 43.4M-2.3% | 44.4M | 0.00 | |
| Operating lease liability (total) | 59.3M-26.8% | 81.0M+63.6% | 49.5M-1.7% | 50.4M | — | |
| Finance lease liability (total) | 18.3M-31.2% | 26.6M | — | — | — | |
| Finance lease liability | 9.37M-48.9% | 18.3M | 0.00 | — | — | |
| Deferred tax liabilities | 23.3M+40.3% | 16.6M+1137.9% | 1.34M | 0.00 | — | |
| Other non-current liabilities | 2.08M-56.0% | 4.73M | 0.00 | — | — | |
| 1.13B+9.3% | 1.03B+123.3% | 463M-4.6% | 486M-10.5% | 543M+363.2% | ||
| Common stock | 5.00K+25.0% | 4.00K+100.0% | 2.00K+0.0% | 2.00K+0.0% | 2.00K | |
| Additional paid-in capital | 3.17B+28.2% | 2.47B+72.9% | 1.43B+27.2% | 1.13B+19.3% | 943M+12798.6% | |
| Retained earnings | -2.08B-45.0% | -1.43B-47.9% | -968M-51.3% | -640M-59.9% | -400M-87.3% | |
| Accumulated other comprehensive income | 36.7M+580.8% | -7.64M | 0.00 | 0.00+100.0% | -126K | |
| Total liabilities & equity | 1.47B+1.8% | 1.45B+121.6% | 654M-6.8% | 701M+14.9% | 610M+104.4% | |
| Common shares issued | 528M+33.1% | 397M+69.4% | 234M+22.6% | 191M+12.2% | 170M+663.1% | |
| Common shares outstanding | 528M+33.1% | 397M+69.4% | 234M+22.6% | 191M+12.2% | 170M+663.1% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -372M-3.5% | -359M-24.8% | -288M-244.5% | -83.5M+47.3% | -159M-249.4% | ||
| Depreciation & amortization | 83.7M+129.4% | 36.5M+49.6% | 24.4M+107.6% | 11.8M+39.9% | 8.40M+113.2% | |
| Intangible amortization | 50.3M+167.6% | 18.8M+121.2% | 8.50M+2142.7% | 379K+24.7% | 304K+141.3% | |
| Share-based compensation | 111M+36.2% | 81.7M+52.7% | 53.5M+91.7% | 27.9M+88.0% | 14.8M+245.8% | |
| Deferred income taxes | -368K+77.4% | -1.63M+59.8% | -4.06M | 0.00 | — | |
| Change in receivables | — | — | — | — | -114K-2380.0% | |
| Change in payables | -2.62M-140.7% | 6.43M+752.0% | -987K-155.9% | 1.77M+1.3% | 1.75M+1043.2% | |
| -16.9M-106.5% | 260M+2642.6% | -10.2M-105.3% | 193M+171.1% | -272M-3009.2% | ||
| Capital expenditure | 6.47M-52.8% | 13.7M+14.6% | 12.0M-67.7% | 37.1M-6.9% | 39.8M+582.5% | |
| Free cash flow | -378M-1.5% | -373M-24.4% | -300M-148.6% | -121M+39.2% | -198M-287.3% | |
| Acquisitions | 0.00+100.0% | -277M-14927.3% | -1.84M | 0.00 | 0.00-100.0% | |
| Purchases of investments | 3.81M | 0.00 | 0.00 | — | — | |
| 522M+71.5% | 304M+117.0% | 140M-9.2% | 154M-66.3% | 459M+86.3% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00-100.0% | 766K+751.1% | 90.0K-99.3% | 12.8M+16520.8% | |
| Common stock issued | 529M+76.0% | 300M+134.5% | 128M-10.9% | 144M-69.0% | 463M | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 18.0M+629.8% | -3.41M-1911.7% | 188K+161.2% | -307K | 0.00 | |
| Net change in cash | 151M-25.1% | 202M+227.8% | -158M-159.8% | 264M+835.9% | 28.2M-85.3% | |
| Interest paid | — | — | 96.0K+74.5% | 55.0K-91.9% | 680K-31.2% | |
| Income taxes paid | 237K | 0.00 | — | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 2.16B-19.5% | 2.68B+25.8% | 2.13B+58.9% | 1.34B-54.0% | 2.92B | |
| P/S | 28.9×-36.5% | 45.6×+1.2% | 45.0×-3.7% | 46.8×-83.7% | 286.6× | |
| P/B | 1.9×-26.3% | 2.6×-46.8% | 4.9×+40.8% | 3.5×-35.6% | 5.4× | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: RXRX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all RXRX filings on SEC EDGAR → Not investment advice.